Maria Domenica Cappellini

TL;DR: It is very important to remove excess iron and suppress LPI to avoid the serious clinical sequelae associated with iron overload.

TL;DR: The Italian Society of Hematology appointed a panel of experts to produce clinical practice-guidelines for the management of iron overload in thalassemia major and related disorders, and the resulting recommendations advise about which examination to carry out in order to planIron chelation therapy, when to start iron chelation, which iron chelator to choose in regularly transfused patients, how to monitor iron chelated therapy, and when and how to switch standard therapy.

TL;DR: There are a number of options currently available for managing patients with β thalassaemia intermedia (TI) including splenectomy, transfusion therapy, iron chelation therapy, modulation of fetal haemoglobin production, and several other agents targeting specific clinical complications as discussed by the authors.

TL;DR: The abnormal phospholipid membrane assymetry present in the red blood cells of β‐thalassaemia and SCA patients, with resultant phosphatidylserine exposure appears to play a significant role in the aetiology of the observed hypercoagulable state.

TL;DR: The use of MRI is described to determine which adult and pediatric patients need to begin iron chelation therapy and to monitor their progress, and the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acceptability, and side effects.